Fig. 3: Higher LEDD and disease severity scores are associated to higher DDC NPX values. | Nature Communications

Fig. 3: Higher LEDD and disease severity scores are associated to higher DDC NPX values.

From: Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment

Fig. 3: Higher LEDD and disease severity scores are associated to higher DDC NPX values.The alternative text for this image may have been generated using AI.

Associations of plasma DDC NPX values with LEDD alone (pink, n individuals = 33, n samples = 96 (a) and in combination with the disease severity scores UPDRS3 (purple, n individuals = 33, n samples = 96 (b), HY (turquoise, n individuals = 33, n samples = 96 (c) and MoCA (green, n individuals = 30, n samples = 50 (d) in the patients with PD of the PPMI Cohort. Association of DDC NPX values and LEDD and disease severity measures were analyzed in the PD group by mixed-effects models, with random effect for each individual and corrected for age and sex and different disease severity scores in (b–d). Dots represent raw DDC measurements, lines represent predicted values based on mixed effects models and transparent areas represent 95% confidence intervals. Source data are provided as a Source Data file. DDC DOPA decarboxylase, HY Hoehn and Yahr scale, LEDD levodopa equivalent daily dosage, MoCA Montreal Cognitive Assessment, NPX normalized protein expression, PD Parkinson’s disease, PPMI Parkinson’s disease Progression Marker Initiative, R2c conditional R squared, R2m marginal R squared, UPDRS3 unified Parkinson’s disease rating scale part 3.

Back to article page